beta

AIMT

Aimmune Therapeutics Inc.

Aimt

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-08-2018 08-08-2018 05-08-2018 03-12-2018 11-06-2017 08-08-2017 05-08-2017
Actual EPS -0.89 -0.91 -0.92 -0.81 -0.63 -0.65 -0.52
Consensus EPS -0.86 -0.79 -0.66 -0.72 -0.72 -0.64 -0.53
Estimated EPS -0.86 -0.79 -0.66 -0.72 -0.72 -0.64 -0.53
Number of Estimates 6 4 5 5 3 3 3
EPS Surprise -$0.03 -$0.12 -$0.26 -$0.09 $0.09 -$0.01 $0.01

Stats

Summary

Aimmune Therapeutics Inc is engaged in the field of biotechnology. It researches and develops drug candidates for the treatment of peanut and other food allergies.

Market Cap: 1.91 Billion

Primary Exchange: Nasdaq Global Select

Website: http://www.aimmune.com

Shares Outstanding: 51.2 Million

Float: 50.4 Million

Dividend: 0.0 (0.0%)

Beta: -0.77665

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 2.62 Million

Ethical Flags

Animal testing

Longest drawdown: 315 trading days

From: 2015-08-14 To: 2016-11-11

Lowest Point:

Aimmune Therapeutics (AIMT) Investor Presentation - Slideshow

via: SeekingAlpha at 2018-12-12 14:44:58:000

The following slide deck was published by Aimmune Therapeutics in conjunction with this Read more … read more...

Aimmune Therapeutics (AIMT) Investor Presentation - Slideshow

via: SeekingAlpha at 2018-12-12 14:44:58:000

The following slide deck was published by Aimmune Therapeutics in conjunction with this Read more … read more...

Aimmune Therapeutics (AIMT) Investor Presentation - Slideshow

via: SeekingAlpha at 2018-12-12 14:44:58:000

The following slide deck was published by Aimmune Therapeutics in conjunction with this Read more … read more...

Stocks To Watch: Tencent Music, Starbucks And Under Armour In Focus

via: SeekingAlpha at 2018-12-08 09:31:22:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are prepping for another week of volatility as concerns over the China tr… read more...

Stocks To Watch: Tencent Music, Starbucks And Under Armour In Focus

via: SeekingAlpha at 2018-12-08 09:31:22:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are prepping for another week of volatility as concerns over the China tr… read more...

Stocks To Watch: Tencent Music, Starbucks And Under Armour In Focus

via: SeekingAlpha at 2018-12-08 09:31:22:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are prepping for another week of volatility as concerns over the China tr… read more...

Aimmune Therapeutics to Host Investor Symposium on the Future of Treating Peanut Allergy with Leading Expert Allergists on Wednesday, December 12th

via: Business Wire at 2018-12-06 08:00:00:000

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 12, 2018. Aimmunes senior management will discuss AR101s clin… read more...

Aimmune Therapeutics to Host Investor Symposium on the Future of Treating Peanut Allergy with Leading Expert Allergists on Wednesday, December 12th

via: Business Wire at 2018-12-06 08:00:00:000

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 12, 2018. Aimmunes senior management will discuss AR101s clin… read more...

Aimmune Therapeutics On Track For Major Breakthrough

via: SeekingAlpha at 2018-11-30 09:00:19:000

It is certainly not without precedent that when clinical stage biotech companies report efficacy and safety data, nervous traders afraid of losing a dime will stampede for the exits at the slightest whiff of trouble. Forget about the fact that most Wall Street traders have not a clue about the… read more...

Aimmune Therapeutics On Track For Major Breakthrough

via: SeekingAlpha at 2018-11-30 09:00:19:000

It is certainly not without precedent that when clinical stage biotech companies report efficacy and safety data, nervous traders afraid of losing a dime will stampede for the exits at the slightest whiff of trouble. Forget about the fact that most Wall Street traders have not a clue about the… read more...

Aimmune Therapeutics On Track For Major Breakthrough

via: SeekingAlpha at 2018-11-30 09:00:19:000

It is certainly not without precedent that when clinical stage biotech companies report efficacy and safety data, nervous traders afraid of losing a dime will stampede for the exits at the slightest whiff of trouble. Forget about the fact that most Wall Street traders have not a clue about the… read more...

Aimmune Therapeutics On Track For Major Breakthrough

via: SeekingAlpha at 2018-11-30 09:00:19:000

It is certainly not without precedent that when clinical stage biotech companies report efficacy and safety data, nervous traders afraid of losing a dime will stampede for the exits at the slightest whiff of trouble. Forget about the fact that most Wall Street traders have not a clue about the… read more...

Aimmune Therapeutics On Track For Major Breakthrough

via: SeekingAlpha at 2018-11-30 09:00:19:000

It is certainly not without precedent that when clinical stage biotech companies report efficacy and safety data, nervous traders afraid of losing a dime will stampede for the exits at the slightest whiff of trouble. Forget about the fact that most Wall Street traders have not a clue about the… read more...

Aimmune Therapeutics Announces Closing of $98 Million Investment by Nestlé Health Science

via: Business Wire at 2018-11-28 16:05:00:000

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the closing of the $98 million equity investment by Nestl Health Science. Nestl Health Science purchased 3,237,529 newly is… read more...

Aimmune Therapeutics Announces Closing of $98 Million Investment by Nestlé Health Science

via: Business Wire at 2018-11-28 16:05:00:000

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the closing of the $98 million equity investment by Nestl Health Science. Nestl Health Science purchased 3,237,529 newly is… read more...

Aimmune up 6% premarket on publication of successful late-stage study of peanut allergy candidate AR101

via: SeekingAlpha at 2018-11-19 06:59:59:000

Aimmune Therapeutics (NASDAQ: AIMT ) is up 6% premarket, albeit on only 800 shares, on the heels of the publication in the New England Journal of Medicine of results from the Phase 3 PALISADE study evaluating AR101 in patients with peanut allergy. More news on: Aimmune Ther… read more...

Aimmune up 6% premarket on publication of successful late-stage study of peanut allergy candidate AR101

via: SeekingAlpha at 2018-11-19 06:59:59:000

Aimmune Therapeutics (NASDAQ: AIMT ) is up 6% premarket, albeit on only 800 shares, on the heels of the publication in the New England Journal of Medicine of results from the Phase 3 PALISADE study evaluating AR101 in patients with peanut allergy. More news on: Aimmune Ther… read more...

Aimmune up 6% premarket on publication of successful late-stage study of peanut allergy candidate AR101

via: SeekingAlpha at 2018-11-19 06:59:59:000

Aimmune Therapeutics (NASDAQ: AIMT ) is up 6% premarket, albeit on only 800 shares, on the heels of the publication in the New England Journal of Medicine of results from the Phase 3 PALISADE study evaluating AR101 in patients with peanut allergy. More news on: Aimmune Ther… read more...

Landmark PALISADE Trial of AR101 Published in New England Journal of Medicine

via: Business Wire at 2018-11-18 16:45:00:000

Treatment with AR101 significantly increased the amount of peanut protein tolerated and reduced the number and severity of reactions to peanut protein Aimmune conference call Monday, November 19 at 8:00 a.m. Eastern Aimmune Therapeutics, Inc. (… read more...

Aimmune Therapeutics Announces Additional Equity Investment by Nestlé Health Science

via: Business Wire at 2018-11-12 08:00:00:000

Nestl Health Science to Invest $98 Million in Aimmune through the Purchase of 3.24 Million Shares of Aimmune Stock at $30.27 per Share Companies Extend Existing Strategic Collaboration Agreement Focused on Offering Innovative Food Allergy Therapies &#x2… read more...

Aimmune Therapeutics Announces Additional Equity Investment by Nestlé Health Science

via: Business Wire at 2018-11-12 08:00:00:000

Nestl Health Science to Invest $98 Million in Aimmune through the Purchase of 3.24 Million Shares of Aimmune Stock at $30.27 per Share Companies Extend Existing Strategic Collaboration Agreement Focused on Offering Innovative Food Allergy Therapies &#x2… read more...

Aimmune Therapeutics Announces Additional Equity Investment by Nestlé Health Science

via: Business Wire at 2018-11-12 08:00:00:000

Nestl Health Science to Invest $98 Million in Aimmune through the Purchase of 3.24 Million Shares of Aimmune Stock at $30.27 per Share Companies Extend Existing Strategic Collaboration Agreement Focused on Offering Innovative Food Allergy Therapies &#x2… read more...

Aimmune Therapeutics EPS in-line

via: SeekingAlpha at 2018-11-08 16:04:29:000

Aimmune Therapeutics (NASDAQ: AIMT ): Q3 GAAP EPS of -$0.89 in-line. Cash and equivalents of $255.2M. Press Release More news on: Aimmune Therapeutics, Earnings news and commentary, Healthcare stocks news, read more...

Aimmune Therapeutics EPS in-line

via: SeekingAlpha at 2018-11-08 16:04:29:000

Aimmune Therapeutics (NASDAQ: AIMT ): Q3 GAAP EPS of -$0.89 in-line. Cash and equivalents of $255.2M. Press Release More news on: Aimmune Therapeutics, Earnings news and commentary, Healthcare stocks news, read more...

Aimmune Therapeutics EPS in-line

via: SeekingAlpha at 2018-11-08 16:04:29:000

Aimmune Therapeutics (NASDAQ: AIMT ): Q3 GAAP EPS of -$0.89 in-line. Cash and equivalents of $255.2M. Press Release More news on: Aimmune Therapeutics, Earnings news and commentary, Healthcare stocks news, read more...

Aimmune Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Highlights

via: Business Wire at 2018-11-08 16:01:00:000

Recently completed Phase 3 RAMSES study confirms safety profile of AR101 in peanut-allergic children and teens BLA submission for AR101 on track for December 2018 Management to host analyst event on Wednesday, December 12 th , in New York Aimmune Therapeutics, Inc. (Nasdaq… read more...

Aimmune Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Highlights

via: Business Wire at 2018-11-08 16:01:00:000

Recently completed Phase 3 RAMSES study confirms safety profile of AR101 in peanut-allergic children and teens BLA submission for AR101 on track for December 2018 Management to host analyst event on Wednesday, December 12 th , in New York Aimmune Therapeutics, Inc. (Nasdaq… read more...

Aimmune Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Highlights

via: Business Wire at 2018-11-08 16:01:00:000

Recently completed Phase 3 RAMSES study confirms safety profile of AR101 in peanut-allergic children and teens BLA submission for AR101 on track for December 2018 Management to host analyst event on Wednesday, December 12 th , in New York Aimmune Therapeutics, Inc. (Nasdaq… read more...

Aimmune Therapeutics Announces Presentations at 2018 ACAAI Annual Scientific Meeting

via: Business Wire at 2018-11-08 08:00:00:000

Oral Presentation on Data from Aimmunes Pivotal Phase 3 PALISADE Trial Additional Oral and E-Poster Presentations on AR101, Peanut Allergy and Oral Immunotherapy Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company deve… read more...

Aimmune Therapeutics Announces Presentations at 2018 ACAAI Annual Scientific Meeting

via: Business Wire at 2018-11-08 08:00:00:000

Oral Presentation on Data from Aimmunes Pivotal Phase 3 PALISADE Trial Additional Oral and E-Poster Presentations on AR101, Peanut Allergy and Oral Immunotherapy Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company deve… read more...

Aimmune Therapeutics Announces Presentations at 2018 ACAAI Annual Scientific Meeting

via: Business Wire at 2018-11-08 08:00:00:000

Oral Presentation on Data from Aimmunes Pivotal Phase 3 PALISADE Trial Additional Oral and E-Poster Presentations on AR101, Peanut Allergy and Oral Immunotherapy Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company deve… read more...

Aimmune Therapeutics Announces Appointment of Dr. Brett Haumann to Board of Directors

via: Business Wire at 2018-11-02 08:00:00:000

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Brett Haumann, M.B.B.Ch., M.B.A., has joined the Aimmune Board of Directors, effective October 31, 2018. Dr. Haumanns exte… read more...

Aimmune Therapeutics Announces Appointment of Dr. Brett Haumann to Board of Directors

via: Business Wire at 2018-11-02 08:00:00:000

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Brett Haumann, M.B.B.Ch., M.B.A., has joined the Aimmune Board of Directors, effective October 31, 2018. Dr. Haumanns exte… read more...

Aimmune Therapeutics Announces Appointment of Dr. Brett Haumann to Board of Directors

via: Business Wire at 2018-11-02 08:00:00:000

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Brett Haumann, M.B.B.Ch., M.B.A., has joined the Aimmune Board of Directors, effective October 31, 2018. Dr. Haumanns exte… read more...

Aimmune Therapeutics Announces Appointment of Dr. Brett Haumann to Board of Directors

via: Business Wire at 2018-11-02 08:00:00:000

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Brett Haumann, M.B.B.Ch., M.B.A., has joined the Aimmune Board of Directors, effective October 31, 2018. Dr. Haumanns exte… read more...

Aimmune Therapeutics Announces Appointment of Dr. Brett Haumann to Board of Directors

via: Business Wire at 2018-11-02 08:00:00:000

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Brett Haumann, M.B.B.Ch., M.B.A., has joined the Aimmune Board of Directors, effective October 31, 2018. Dr. Haumanns exte… read more...

Aimmune Therapeutics to Participate in Upcoming Investor Conferences

via: Business Wire at 2018-11-01 08:00:00:000

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of senior management will participate in the following investor conferences: Stifel 2018 Healthcare Conference (November 13, … read more...

Aimmune teams up with Regeneron and Sanofi in mid-stage peanut allergy study; shares up 1%

via: SeekingAlpha at 2018-10-15 10:43:22:000

Aimmune Therapeutics ( AIMT +1.3% ) is up on light volume on the heels of the initiation of a Phase 2 clinical trial evaluating AR101 with adjunctive DUPIXENT (dupilumab) in peanut-allergy patients. More news on: Aimmune Therapeutics, Regeneron Pharmaceuticals, Inc., Sanofi, Healthca… read more...

Aimmune teams up with Regeneron and Sanofi in mid-stage peanut allergy study; shares up 1%

via: SeekingAlpha at 2018-10-15 10:43:22:000

Aimmune Therapeutics ( AIMT +1.3% ) is up on light volume on the heels of the initiation of a Phase 2 clinical trial evaluating AR101 with adjunctive DUPIXENT (dupilumab) in peanut-allergy patients. More news on: Aimmune Therapeutics, Regeneron Pharmaceuticals, Inc., Sanofi, Healthca… read more...

Aimmune teams up with Regeneron and Sanofi in mid-stage peanut allergy study; shares up 1%

via: SeekingAlpha at 2018-10-15 10:43:22:000

Aimmune Therapeutics ( AIMT +1.3% ) is up on light volume on the heels of the initiation of a Phase 2 clinical trial evaluating AR101 with adjunctive DUPIXENT (dupilumab) in peanut-allergy patients. More news on: Aimmune Therapeutics, Regeneron Pharmaceuticals, Inc., Sanofi, Healthca… read more...

Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101 With Adjunctive Dupilumab in Peanut-Allergic Patients

via: Business Wire at 2018-10-15 08:00:00:000

Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101 Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2 study ,… read more...

Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101 With Adjunctive Dupilumab in Peanut-Allergic Patients

via: Business Wire at 2018-10-15 08:00:00:000

Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101 Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2 study ,… read more...

Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101 With Adjunctive Dupilumab in Peanut-Allergic Patients

via: Business Wire at 2018-10-15 08:00:00:000

Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101 Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2 study ,… read more...

With life-threatening food allergies on the rise, drug companies ramp up new approaches

via: CNBC at 2018-09-27 14:46:00:000

No summary available. read more...

With life-threatening food allergies on the rise, drug companies ramp up new approaches

via: CNBC at 2018-09-27 14:46:00:000

No summary available. read more...

With life-threatening food allergies on the rise, drug companies ramp up new approaches

via: CNBC at 2018-09-27 14:46:00:000

No summary available. read more...

Aimmune Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 3

via: Business Wire at 2018-09-26 08:00:00:000

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that President and CEO Jayson Dallas, M.D., will participate in a fireside chat at the Cantor Global Healthcare Conference in New York on Wednesda… read more...

Aimmune: To Capture The Vast Food Allergy Market

via: SeekingAlpha at 2018-09-24 14:38:25:000

The correct attitude of the security analyst toward the stock market might well be that of a man toward his wife. He shouldnt pay too much attention to what the lady says, but he cant afford to ignore it entirely. That is pretty much the position that most of us find ourselves… read more...

Aimmune: To Capture The Vast Food Allergy Market

via: SeekingAlpha at 2018-09-24 14:38:25:000

The correct attitude of the security analyst toward the stock market might well be that of a man toward his wife. He shouldnt pay too much attention to what the lady says, but he cant afford to ignore it entirely. That is pretty much the position that most of us find ourselves… read more...

Intrommune advancing peanut allergy candidate, pre-IND meeting with FDA completed

via: SeekingAlpha at 2018-09-06 11:15:06:000

Privately held Intromune Therapeutics met recently with the FDA to discuss the details of an IND for INT301, an immunotherapy to treat peanut allergy. Once approved, clinical studies may begin. More news on: AnaptysBio, Aimmune Therapeutics, DBV Technologies, Healthcare stocks news, … read more...

Intrommune advancing peanut allergy candidate, pre-IND meeting with FDA completed

via: SeekingAlpha at 2018-09-06 11:15:06:000

Privately held Intromune Therapeutics met recently with the FDA to discuss the details of an IND for INT301, an immunotherapy to treat peanut allergy. Once approved, clinical studies may begin. More news on: AnaptysBio, Aimmune Therapeutics, DBV Technologies, Healthcare stocks news, … read more...

Intrommune advancing peanut allergy candidate, pre-IND meeting with FDA completed

via: SeekingAlpha at 2018-09-06 11:15:06:000

Privately held Intromune Therapeutics met recently with the FDA to discuss the details of an IND for INT301, an immunotherapy to treat peanut allergy. Once approved, clinical studies may begin. More news on: AnaptysBio, Aimmune Therapeutics, DBV Technologies, Healthcare stocks news, … read more...

Aimmune Therapeutics to Present at Three Investor Conferences in September

via: Business Wire at 2018-08-29 08:00:00:000

Wells Fargo Healthcare Conference, September 5 Baird Global Healthcare Conference, September 6 Bank of America Merrill Lynch Global Healthcare Conference, September 12 Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life… read more...

Aimmune Therapeutics to Present at Three Investor Conferences in September

via: Business Wire at 2018-08-29 08:00:00:000

Wells Fargo Healthcare Conference, September 5 Baird Global Healthcare Conference, September 6 Bank of America Merrill Lynch Global Healthcare Conference, September 12 Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life… read more...

Aimmune Therapeutics to Present at Three Investor Conferences in September

via: Business Wire at 2018-08-29 08:00:00:000

Wells Fargo Healthcare Conference, September 5 Baird Global Healthcare Conference, September 6 Bank of America Merrill Lynch Global Healthcare Conference, September 12 Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life… read more...

Here, Take Another Hit Of This, Then Sell Some More Aimmune

via: SeekingAlpha at 2018-08-13 21:03:06:000

Once again investors have smoked the strong stuff and sold Aimmune Therapeutics (AIMT) to levels that underprice its true value and potential. More patient - read thoughtful - investors should find these valuations compelling and an excellent entry point. Aimmune has fallen significantly below… read more...

Here, Take Another Hit Of This, Then Sell Some More Aimmune

via: SeekingAlpha at 2018-08-13 21:03:06:000

Once again investors have smoked the strong stuff and sold Aimmune Therapeutics (AIMT) to levels that underprice its true value and potential. More patient - read thoughtful - investors should find these valuations compelling and an excellent entry point. Aimmune has fallen significantly below… read more...

Here, Take Another Hit Of This, Then Sell Some More Aimmune

via: SeekingAlpha at 2018-08-13 21:03:06:000

Once again investors have smoked the strong stuff and sold Aimmune Therapeutics (AIMT) to levels that underprice its true value and potential. More patient - read thoughtful - investors should find these valuations compelling and an excellent entry point. Aimmune has fallen significantly below… read more...

Aimmune And DBV Technologies: A Comparison

via: SeekingAlpha at 2018-08-13 03:59:25:000

Last year, I was quietly rooting for DBV technologies ( DBVT ) mainly because they are an European company relatively less known in the US, thus offering a solid diversification avenue. However, trial results have shown that Aimmune ( AIMT ) is probably the better drug, and although the news i… read more...

Aimmune Therapeutics misses by $0.05

via: SeekingAlpha at 2018-08-08 16:13:49:000

Aimmune Therapeutics (NASDAQ: AIMT ): Q2 EPS of -$0.91 misses by $0.05 . More news on: Aimmune Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Aimmune Therapeutics misses by $0.05

via: SeekingAlpha at 2018-08-08 16:13:49:000

Aimmune Therapeutics (NASDAQ: AIMT ): Q2 EPS of -$0.91 misses by $0.05 . More news on: Aimmune Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Aimmune Therapeutics misses by $0.05

via: SeekingAlpha at 2018-08-08 16:13:49:000

Aimmune Therapeutics (NASDAQ: AIMT ): Q2 EPS of -$0.91 misses by $0.05 . More news on: Aimmune Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Aimmune Therapeutics Announces Second Quarter 2018 Financial Results

via: Business Wire at 2018-08-08 16:01:00:000

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2018. As of June 30, 2018, cash, cash equivalents and investments totaled $295.9 m… read more...

Aimmune Therapeutics Announces Second Quarter 2018 Financial Results

via: Business Wire at 2018-08-08 16:01:00:000

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2018. As of June 30, 2018, cash, cash equivalents and investments totaled $295.9 m… read more...

Aimmune Therapeutics Announces Second Quarter 2018 Financial Results

via: Business Wire at 2018-08-08 16:01:00:000

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2018. As of June 30, 2018, cash, cash equivalents and investments totaled $295.9 m… read more...

Aimmune Therapeutics Announces CEO Jayson Dallas Will Present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th

via: Business Wire at 2018-08-07 08:00:00:000

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas, M.D., will give his first public presentation as the companys President and CEO at the 2018 Wedbush PacGrow Healthcare… read more...

3 Solid Mid-Cap Biotechs To Close Out 2018

via: SeekingAlpha at 2018-07-22 08:38:55:000

Ah, Winter will be here before we know it. Below are three mid-cap biotechnology stocks I believe have great risk/reward ratios and significant remaining upside before the dead of Winter hits (January). All of the mid-cap picks I present: have high cash/low debt are technical momentu… read more...

3 Solid Mid-Cap Biotechs To Close Out 2018

via: SeekingAlpha at 2018-07-22 08:38:55:000

Ah, Winter will be here before we know it. Below are three mid-cap biotechnology stocks I believe have great risk/reward ratios and significant remaining upside before the dead of Winter hits (January). All of the mid-cap picks I present: have high cash/low debt are technical momentu… read more...

3 Solid Mid-Cap Biotechs To Close Out 2018

via: SeekingAlpha at 2018-07-22 08:38:55:000

Ah, Winter will be here before we know it. Below are three mid-cap biotechnology stocks I believe have great risk/reward ratios and significant remaining upside before the dead of Winter hits (January). All of the mid-cap picks I present: have high cash/low debt are technical momentu… read more...

Aimmune: Societal Benefits

via: SeekingAlpha at 2018-07-19 18:47:06:000

Anybody with kids know that peanut allergies are not only life-threatening to people with the immune deficiency but also a societal impact causing all parents to watch what food they send to school. Aimmune Therapeutics ( AIMT ) offers a possible solution that might help solve food allergies… read more...

Aimmune: Societal Benefits

via: SeekingAlpha at 2018-07-19 18:47:06:000

Anybody with kids know that peanut allergies are not only life-threatening to people with the immune deficiency but also a societal impact causing all parents to watch what food they send to school. Aimmune Therapeutics ( AIMT ) offers a possible solution that might help solve food allergies… read more...

Aimmune: Societal Benefits

via: SeekingAlpha at 2018-07-19 18:47:06:000

Anybody with kids know that peanut allergies are not only life-threatening to people with the immune deficiency but also a societal impact causing all parents to watch what food they send to school. Aimmune Therapeutics ( AIMT ) offers a possible solution that might help solve food allergies… read more...

SA Interview: Event-Driven Investing With Panther Investments

via: SeekingAlpha at 2018-07-01 07:30:00:000

Feature interview Panther Investments is focused on long/short investing with a value-oriented, event-driven focus. We emailed with Panther Investments about when to follow (and not to) high profile investors and management teams into a stock, how to determine if the only one to benefit … read more...

SA Interview: Event-Driven Investing With Panther Investments

via: SeekingAlpha at 2018-07-01 07:30:00:000

Feature interview Panther Investments is focused on long/short investing with a value-oriented, event-driven focus. We emailed with Panther Investments about when to follow (and not to) high profile investors and management teams into a stock, how to determine if the only one to benefit … read more...

SA Interview: Event-Driven Investing With Panther Investments

via: SeekingAlpha at 2018-07-01 07:30:00:000

Feature interview Panther Investments is focused on long/short investing with a value-oriented, event-driven focus. We emailed with Panther Investments about when to follow (and not to) high profile investors and management teams into a stock, how to determine if the only one to benefit … read more...

With food allergies on the rise, biotech Aimmune is focusing on raising patients' tolerance

via: CNBC at 2018-06-28 14:30:00:000

No summary available. read more...

With food allergies on the rise, biotech Aimmune is focusing on raising patients' tolerance

via: CNBC at 2018-06-28 14:30:00:000

No summary available. read more...

With food allergies on the rise, biotech Aimmune is focusing on raising patients' tolerance

via: CNBC at 2018-06-28 14:30:00:000

No summary available. read more...

Market Keeps Rewarding Growth - Cramer's Mad Money (6/20/18)

via: SeekingAlpha at 2018-06-21 07:38:46:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday , June 20. Yes, the markets trade on interest rate hike and tariff fears but in reality, it loves growth. That's what happened with the Twenty First Century Fox ([[FOX]], [[FOXA]]), which say a … read more...

Market Keeps Rewarding Growth - Cramer's Mad Money (6/20/18)

via: SeekingAlpha at 2018-06-21 07:38:46:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday , June 20. Yes, the markets trade on interest rate hike and tariff fears but in reality, it loves growth. That's what happened with the Twenty First Century Fox ([[FOX]], [[FOXA]]), which say a … read more...

Cramer Remix: The battle between these stocks proves why tech triumphs

via: CNBC at 2018-06-20 19:00:00:000

No summary available. read more...

Institutional Top Ideas: Great Point Partners

via: SeekingAlpha at 2018-06-19 05:55:30:000

In the last entry of this series we took a look at top ideas from Cormorant Asset Management, a hedge fund with high returns, relatively high turnover and heavily overweight in their top three holdings. This is the last entry in the Institutional Top Ideas series (for now)- as usual we try… read more...

Institutional Top Ideas: Great Point Partners

via: SeekingAlpha at 2018-06-19 05:55:30:000

In the last entry of this series we took a look at top ideas from Cormorant Asset Management, a hedge fund with high returns, relatively high turnover and heavily overweight in their top three holdings. This is the last entry in the Institutional Top Ideas series (for now)- as usual we try… read more...

Aimmune Therapeutics (AIMT) Presents At 38th Nasdaq Investor Conference - Slideshow

via: SeekingAlpha at 2018-06-13 14:17:08:000

The following slide deck was published by Aimmune Therapeutics in conjunction with this Read more … read more...

Aimmune Therapeutics (AIMT) Presents At 38th Nasdaq Investor Conference - Slideshow

via: SeekingAlpha at 2018-06-13 14:17:08:000

The following slide deck was published by Aimmune Therapeutics in conjunction with this Read more … read more...

Aimmune Therapeutics (AIMT) Presents At 38th Nasdaq Investor Conference - Slideshow

via: SeekingAlpha at 2018-06-13 14:17:08:000

The following slide deck was published by Aimmune Therapeutics in conjunction with this Read more … read more...

Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO

via: Business Wire at 2018-06-11 16:01:00:000

Experienced Leader Brings Extensive Record of Global Strategic and Commercial Operational Accomplishments and Successful Product Launches Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food… read more...

Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO

via: Business Wire at 2018-06-11 16:01:00:000

Experienced Leader Brings Extensive Record of Global Strategic and Commercial Operational Accomplishments and Successful Product Launches Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food… read more...

Aimmune Therapeutics: Special Situation Biotech Opportunity

via: SeekingAlpha at 2018-06-08 12:24:25:000

Overview: Millions of Americans suffer from food allergies, with peanut allergy being the most popular among those. Aimmune's CODIT (Characterized Oral Desensitization ImmunoTherapy) therapy is designed to be a one-time series of treatments that raises a patient's tolerance of peanuts enou… read more...

Aimmune Therapeutics: Special Situation Biotech Opportunity

via: SeekingAlpha at 2018-06-08 12:24:25:000

Overview: Millions of Americans suffer from food allergies, with peanut allergy being the most popular among those. Aimmune's CODIT (Characterized Oral Desensitization ImmunoTherapy) therapy is designed to be a one-time series of treatments that raises a patient's tolerance of peanuts enou… read more...

Aimmune Therapeutics: Special Situation Biotech Opportunity

via: SeekingAlpha at 2018-06-08 12:24:25:000

Overview: Millions of Americans suffer from food allergies, with peanut allergy being the most popular among those. Aimmune's CODIT (Characterized Oral Desensitization ImmunoTherapy) therapy is designed to be a one-time series of treatments that raises a patient's tolerance of peanuts enou… read more...

The Eleven: Viking Skyrockets, Global Blood Is Fueling

via: SeekingAlpha at 2018-06-04 01:02:05:000

The Eleven The Eleven is a biotechnology portfolio of eleven stocks we believe have significant upside within a six month to one-year timeframe based upon company fundamentals and upcoming catalysts with good risk/reward ratios. They are listed in a way to reflect top picks and risk toleran… read more...

The Eleven: Viking Skyrockets, Global Blood Is Fueling

via: SeekingAlpha at 2018-06-04 01:02:05:000

The Eleven The Eleven is a biotechnology portfolio of eleven stocks we believe have significant upside within a six month to one-year timeframe based upon company fundamentals and upcoming catalysts with good risk/reward ratios. They are listed in a way to reflect top picks and risk toleran… read more...

The Eleven: Viking Skyrockets, Global Blood Is Fueling

via: SeekingAlpha at 2018-06-04 01:02:05:000

The Eleven The Eleven is a biotechnology portfolio of eleven stocks we believe have significant upside within a six month to one-year timeframe based upon company fundamentals and upcoming catalysts with good risk/reward ratios. They are listed in a way to reflect top picks and risk toleran… read more...

Aimmune Therapeutics Announces New Pan-European Study Showing Significant Psychosocial Burden Associated With Peanut Allergy

via: Business Wire at 2018-05-30 06:00:00:000

European APPEAL ( A llergy to P eanuts Im p acting E motions a nd L ife) Study Finds Peanut Allergy Has a Daily Impact on More than 80% of People with Peanut Allergy and Parents or Caregivers of Peanut-Allergic Minors Data Discussed at EAACI 2018 Reveal U… read more...

Aimmune Therapeutics Announces New Pan-European Study Showing Significant Psychosocial Burden Associated With Peanut Allergy

via: Business Wire at 2018-05-30 06:00:00:000

European APPEAL ( A llergy to P eanuts Im p acting E motions a nd L ife) Study Finds Peanut Allergy Has a Daily Impact on More than 80% of People with Peanut Allergy and Parents or Caregivers of Peanut-Allergic Minors Data Discussed at EAACI 2018 Reveal U… read more...

Aimmune Therapeutics Announces New Pan-European Study Showing Significant Psychosocial Burden Associated With Peanut Allergy

via: Business Wire at 2018-05-30 06:00:00:000

European APPEAL ( A llergy to P eanuts Im p acting E motions a nd L ife) Study Finds Peanut Allergy Has a Daily Impact on More than 80% of People with Peanut Allergy and Parents or Caregivers of Peanut-Allergic Minors Data Discussed at EAACI 2018 Reveal U… read more...

Aimmune Therapeutics Announces Data on Terminology Used with Oral Immunotherapy Were Presented at EAACI 2018

via: Business Wire at 2018-05-29 07:30:00:000

In U.S. Survey, Allergists Want Consensus in Oral Immunotherapy Terminology U.S. Allergists Preferred Tolerated Dose as the Most Clinically Relevant Term to Communicate Desensitization Levels to Oral Immunotherapy Patients Aimmu… read more...

Aimmune Therapeutics Announces Data on Terminology Used with Oral Immunotherapy Were Presented at EAACI 2018

via: Business Wire at 2018-05-29 07:30:00:000

In U.S. Survey, Allergists Want Consensus in Oral Immunotherapy Terminology U.S. Allergists Preferred Tolerated Dose as the Most Clinically Relevant Term to Communicate Desensitization Levels to Oral Immunotherapy Patients Aimmu… read more...

Aimmune Therapeutics Announces Data on Terminology Used with Oral Immunotherapy Were Presented at EAACI 2018

via: Business Wire at 2018-05-29 07:30:00:000

In U.S. Survey, Allergists Want Consensus in Oral Immunotherapy Terminology U.S. Allergists Preferred Tolerated Dose as the Most Clinically Relevant Term to Communicate Desensitization Levels to Oral Immunotherapy Patients Aimmu… read more...

Aimmune Therapeutics Announces New Clinical Data on AR101 for Peanut Allergy at the 2018 EAACI Congress

via: Business Wire at 2018-05-28 11:15:00:000

New analyses including adults enrolled in the Phase 3 PALISADE trial of AR101 show efficacy across the entire intent-to-treat population of peanut-allergic patients ages 4-55 New immunologic subset analyses show that AR101 treatment was linked to depletion of peanut-specific TH2A cells… read more...

Aimmune Therapeutics Announces New Clinical Data on AR101 for Peanut Allergy at the 2018 EAACI Congress

via: Business Wire at 2018-05-28 11:15:00:000

New analyses including adults enrolled in the Phase 3 PALISADE trial of AR101 show efficacy across the entire intent-to-treat population of peanut-allergic patients ages 4-55 New immunologic subset analyses show that AR101 treatment was linked to depletion of peanut-specific TH2A cells… read more...

Aimmune Therapeutics Announces New Clinical Data on AR101 for Peanut Allergy at the 2018 EAACI Congress

via: Business Wire at 2018-05-28 11:15:00:000

New analyses including adults enrolled in the Phase 3 PALISADE trial of AR101 show efficacy across the entire intent-to-treat population of peanut-allergic patients ages 4-55 New immunologic subset analyses show that AR101 treatment was linked to depletion of peanut-specific TH2A cells… read more...

Reader Inquiry: How Has The Thesis Changed For Aimmune Therapeutics?

via: SeekingAlpha at 2018-05-27 16:39:18:000

Shares of Aimmune Therapeutics ( AIMT ) have risen by over 60% since my first article in early 2017 called the stock a solid runner of the year candidate. While I wrote an update piece later in the year, I continue to receive questions from several readers and ROTY members on whe… read more...

Reader Inquiry: How Has The Thesis Changed For Aimmune Therapeutics?

via: SeekingAlpha at 2018-05-27 16:39:18:000

Shares of Aimmune Therapeutics ( AIMT ) have risen by over 60% since my first article in early 2017 called the stock a solid runner of the year candidate. While I wrote an update piece later in the year, I continue to receive questions from several readers and ROTY members on whe… read more...

Reader Inquiry: How Has The Thesis Changed For Aimmune Therapeutics?

via: SeekingAlpha at 2018-05-27 16:39:18:000

Shares of Aimmune Therapeutics ( AIMT ) have risen by over 60% since my first article in early 2017 called the stock a solid runner of the year candidate. While I wrote an update piece later in the year, I continue to receive questions from several readers and ROTY members on whe… read more...

Reader Inquiry: How Has The Thesis Changed For Aimmune Therapeutics?

via: SeekingAlpha at 2018-05-27 16:39:18:000

Shares of Aimmune Therapeutics ( AIMT ) have risen by over 60% since my first article in early 2017 called the stock a solid runner of the year candidate. While I wrote an update piece later in the year, I continue to receive questions from several readers and ROTY members on whe… read more...

Rounds Report: Aimmune Is Gaining Momentum While Editas Experiences Significant Insider Purchases

via: SeekingAlpha at 2018-05-24 02:29:09:000

The intelligent investor shouldnt ignore Mr. Market entirely. Instead, you should do business with him- but only to the extent that it serves your interests. - Benjamin Graham Trading Analytics Welcome to this edition of Integrated BioSci Rounds Report for May 22, 2018. As usua… read more...

Rounds Report: Aimmune Is Gaining Momentum While Editas Experiences Significant Insider Purchases

via: SeekingAlpha at 2018-05-24 02:29:09:000

The intelligent investor shouldnt ignore Mr. Market entirely. Instead, you should do business with him- but only to the extent that it serves your interests. - Benjamin Graham Trading Analytics Welcome to this edition of Integrated BioSci Rounds Report for May 22, 2018. As usua… read more...

Rounds Report: Aimmune Is Gaining Momentum While Editas Experiences Significant Insider Purchases

via: SeekingAlpha at 2018-05-24 02:29:09:000

The intelligent investor shouldnt ignore Mr. Market entirely. Instead, you should do business with him- but only to the extent that it serves your interests. - Benjamin Graham Trading Analytics Welcome to this edition of Integrated BioSci Rounds Report for May 22, 2018. As usua… read more...

Rounds Report: Aimmune Is Gaining Momentum While Editas Experiences Significant Insider Purchases

via: SeekingAlpha at 2018-05-24 02:29:09:000

The intelligent investor shouldnt ignore Mr. Market entirely. Instead, you should do business with him- but only to the extent that it serves your interests. - Benjamin Graham Trading Analytics Welcome to this edition of Integrated BioSci Rounds Report for May 22, 2018. As usua… read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Lucky Seven: Bio Struggles, Achaogen Breaks Key Support

via: SeekingAlpha at 2018-05-21 23:22:11:000

Micron's ( MU ) raise before earnings and softened trade-war talk with China may have shifted money towards tech and away from biotech. Or, at least, it's nice to think that way. Not only did we see a sea of red, but we saw a member of the green boxes say, in capital letters, "EW". How rud… read more...

Aimmune Nearing Critical Point In Valuation

via: SeekingAlpha at 2018-05-20 15:30:56:000

According to its website : Aimmune is a clinical-stage biopharmaceutical company developing proprietary product candidates and advancing a therapeutic approach for the treatment of peanut and other food allergies. Aimmune Therapeutics (AIMT) has one late-stage drug in AR101 and two prec… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-05-18 16:37:17:000

Noteworthy events during the week of May 20 - 26 for healthcare investors: More news on: uniQure N.V., Roche Holding Ltd ADR, BioMarin Pharmaceutical Inc., Healthcare stocks news, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-18 08:57:57:000

Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Overweight rating and $60 (100% upside) price target at Piper Jaffray. More news on: Aimmune Therapeutics, Alpine Immune Sciences, Inc., Amneal Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock

via: SeekingAlpha at 2018-05-16 12:00:51:000

Editor's note: Seeking Alpha is proud to welcome Sleeps Well At Night as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more They… read more...

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock

via: SeekingAlpha at 2018-05-16 12:00:51:000

Editor's note: Seeking Alpha is proud to welcome Sleeps Well At Night as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more They… read more...

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock

via: SeekingAlpha at 2018-05-16 12:00:51:000

Editor's note: Seeking Alpha is proud to welcome Sleeps Well At Night as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more They… read more...

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock

via: SeekingAlpha at 2018-05-16 12:00:51:000

Editor's note: Seeking Alpha is proud to welcome Sleeps Well At Night as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more They… read more...

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock

via: SeekingAlpha at 2018-05-16 12:00:51:000

Editor's note: Seeking Alpha is proud to welcome Sleeps Well At Night as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more They… read more...

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock

via: SeekingAlpha at 2018-05-16 12:00:51:000

Editor's note: Seeking Alpha is proud to welcome Sleeps Well At Night as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more They… read more...

Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018

via: Business Wire at 2018-05-15 08:00:00:000

Late-Breaking Oral Presentations on AR101 Phase 3 PALISADE Results in Peanut-Allergic Children and Adults and on European Study of Psychosocial Impact of Peanut Allergy Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for po… read more...

Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018

via: Business Wire at 2018-05-15 08:00:00:000

Late-Breaking Oral Presentations on AR101 Phase 3 PALISADE Results in Peanut-Allergic Children and Adults and on European Study of Psychosocial Impact of Peanut Allergy Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for po… read more...

Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018

via: Business Wire at 2018-05-15 08:00:00:000

Late-Breaking Oral Presentations on AR101 Phase 3 PALISADE Results in Peanut-Allergic Children and Adults and on European Study of Psychosocial Impact of Peanut Allergy Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for po… read more...

Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018

via: Business Wire at 2018-05-15 08:00:00:000

Late-Breaking Oral Presentations on AR101 Phase 3 PALISADE Results in Peanut-Allergic Children and Adults and on European Study of Psychosocial Impact of Peanut Allergy Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for po… read more...

Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018

via: Business Wire at 2018-05-15 08:00:00:000

Late-Breaking Oral Presentations on AR101 Phase 3 PALISADE Results in Peanut-Allergic Children and Adults and on European Study of Psychosocial Impact of Peanut Allergy Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for po… read more...

Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018

via: Business Wire at 2018-05-15 08:00:00:000

Late-Breaking Oral Presentations on AR101 Phase 3 PALISADE Results in Peanut-Allergic Children and Adults and on European Study of Psychosocial Impact of Peanut Allergy Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for po… read more...

Aimmune Therapeutics to Participate in Four Upcoming Investor Conferences in May and June

via: Business Wire at 2018-05-09 08:00:00:000

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor conferences in May and June: Event : Bank of… read more...

Aimmune Therapeutics to Participate in Four Upcoming Investor Conferences in May and June

via: Business Wire at 2018-05-09 08:00:00:000

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor conferences in May and June: Event : Bank of… read more...

Aimmune Therapeutics Announces First Quarter 2018 Financial Results

via: Business Wire at 2018-05-08 16:01:00:000

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the first quarter 2018. As of March 31, 2018, cash, cash equivalents and investments totaled $331.7 million. We … read more...

Aimmune Therapeutics Announces First Quarter 2018 Financial Results

via: Business Wire at 2018-05-08 16:01:00:000

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the first quarter 2018. As of March 31, 2018, cash, cash equivalents and investments totaled $331.7 million. We … read more...

Backing Blackstone For A Decade - Cramer's Lightning Round (4/23/18)

via: SeekingAlpha at 2018-04-24 06:50:40:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, April 23. Bullish Calls Ingersoll-Rand plc (IR): This is the kind of industrial stock that works in a tightening environment. Blackstone Group (BX): Cramer has been backing the stock for 10 years… read more...

Aimmune Still Leads In The Peanut Allergy Race

via: SeekingAlpha at 2018-04-02 11:49:58:000

One of the main recent stumbling blocks to upward movement in Aimmunes (AIMT) stock has been concern coming from a perceived existential threat to Aimmunes prospects from AnaptysBios (ANAB) monoclonal antibody approach to treating peanut allergy. Since the release of Ai… read more...

Institutional Top Ideas Series: Deerfield Management

via: SeekingAlpha at 2018-03-28 18:55:28:000

In the first entry of this recently rebooted series, we took a look at top ideas from Consonance Capital (whose performance almost tripled that of the IBB during time frame we looked at). Keep in mind articles older than 10 days can only be accessed if you have a membership to ROTY or Se… read more...

After-hours buzz: RHT, ANAB & more

via: CNBC at 2018-03-26 17:34:00:000

No summary available. read more...

3 Things In Biotech, March 7: Aimmune Scores, Bristol-Myers Compresses, Dermira Bombs

via: SeekingAlpha at 2018-03-08 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

Aimmune Therapeutics to Participate in Four Investor Conferences in March

via: Business Wire at 2018-03-07 08:00:00:000

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor conferences in March: Event: 30th Annual RO… read more...

Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress

via: Business Wire at 2018-02-12 08:15:00:000

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data during a late-breaking oral abstract session and in poster sessions at the 2018 American Academy of Allergy, … read more...

Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress

via: Business Wire at 2018-02-12 08:15:00:000

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data during a late-breaking oral abstract session and in poster sessions at the 2018 American Academy of Allergy, … read more...

Biotech Forum Daily Digest For February 7th

via: SeekingAlpha at 2018-02-07 14:39:18:000

Anyone who has a continuous smile on his face conceals a toughness that is almost frightening . Greta Garbo The biotech sector continues to be volatile like the rest of the market. After big losses Monday when the Dow dropped nearly 1,100, the main biotech indices spent m… read more...

Biotech Forum Daily Digest For February 7th

via: SeekingAlpha at 2018-02-07 14:39:18:000

Anyone who has a continuous smile on his face conceals a toughness that is almost frightening . Greta Garbo The biotech sector continues to be volatile like the rest of the market. After big losses Monday when the Dow dropped nearly 1,100, the main biotech indices spent m… read more...

Biotech Forum Daily Digest For February 7th

via: SeekingAlpha at 2018-02-07 14:39:18:000

Anyone who has a continuous smile on his face conceals a toughness that is almost frightening . Greta Garbo The biotech sector continues to be volatile like the rest of the market. After big losses Monday when the Dow dropped nearly 1,100, the main biotech indices spent m… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-02-07 07:54:07:000

Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Outperform rating and $55 (54% upside) at RBC. More news on: Aimmune Therapeutics, Acorda Therapeutics, Inc., Healthcare Services Group, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-02-07 07:54:07:000

Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Outperform rating and $55 (54% upside) at RBC. More news on: Aimmune Therapeutics, Acorda Therapeutics, Inc., Healthcare Services Group, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-02-07 07:54:07:000

Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Outperform rating and $55 (54% upside) at RBC. More news on: Aimmune Therapeutics, Acorda Therapeutics, Inc., Healthcare Services Group, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Your Daily Pharma Scoop: Lipocine's Gloomy Future, Puma Labeling Change, Concert's Mixed Day

via: SeekingAlpha at 2018-01-13 08:00:00:000

Today we will discuss the Ad Com's vote against Lipocine's ( LPCN ) TLANDO. The news sparked a huge sell-off in LPCN on Wednesday. Few days before the Ad Com, we had written a note on LPCN, highlighting that it is a binary event. TLANDO had been rejected by the FDA in 2016, which pushed LPCN… read more...

Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy

via: Business Wire at 2018-01-10 08:00:00:000

Newly Expanded Global Agreement Secures Exclusive Supply Relationship through 2033 Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced an expansion and extensio… read more...

Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy

via: Business Wire at 2018-01-08 08:00:00:000

PALISADE Completed in 2017; Topline Results Anticipated in February Late-Breaking Abstract Presentation at the 2018 American Academy of Allergy, Asthma & ImmunologyWorld Allergy Organization Joint Congress in March PALISADE … read more...

Aimmune Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

via: Business Wire at 2018-01-03 08:00:00:000

Presentation on Wednesday, January 10, 2018, at 7:30 a.m. Pacific Time Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will pres… read more...

Your Daily Pharma Scoop: AEterna Zentaris Gets FDA Nod, Valeant Finalizes Sprout Sale, Roche Gets EC Approval

via: SeekingAlpha at 2017-12-21 09:42:09:000

Content Analysis of coverage: AEZS Stocks in the news: Analyst Ratings Insider Sales Insider Purchases Secondary Offerings Earnings Report Earnings Calendar Catalyst Rundown Analysis of top Seeking Alpha coverage: AEterna Zentaris Today we will foc… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2017-12-21 08:37:12:000

Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Outperform rating and $64 (76% upside) price target by Robert Baird. More news on: Aimmune Therapeutics, bluebird bio, Inc., Kura Oncology, Healthcare stocks news, Stocks on the move, Read more … read more...

Aimmune Therapeutics - Desensitize Yourself For A Good Bet!

via: SeekingAlpha at 2017-12-20 17:10:08:000

Have you ever noticed a disclaimer on packaging that states that a product was manufactured in a facility that also handles peanuts? Of course you have! Peanut allergies are terrifying to parents worldwide, peanut allergy is the most common form of food related death across the globe and curre… read more...

Your Daily Pharma Scoop: Right Time To Buy Regeneron, Eli Lilly Gives Guidance, Bluebird Announces Offering

via: SeekingAlpha at 2017-12-14 04:07:55:000

Content Analysis of coverage: REGN Stocks in the news: LLY, SNY, BLUE Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Trade Idea of the Day (for TPT subscribers only) Subscriber Questions & An… read more...

Aimmune Therapeutics to Participate in the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14

via: Business Wire at 2017-12-07 08:00:00:000

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Chief Financial Officer Eric Bjerkholt will participate in a fireside chat at the BMO Capital Markets 2017 Prescriptions for Success Healthca… read more...

Your Daily Pharma Scoop: Gilead's Potential, Celgene CAR-T Candidate, Cellectar Soars

via: SeekingAlpha at 2017-12-07 08:00:00:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day ea… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX